All In Biotech

Drug Trial Radar · NCT02308501

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy

Last checked: Nov 20, 2026Latest source record: Mar 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Dec 2014

Primary completion

Feb 2015

Study completion Feb 2015

Sponsor

Lead sponsor
ORA, Inc.Industry
Sponsor type
Industry
First posted
Dec 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by In-Vivo Confocal Microscopy

Conditions

  • Allergic Conjunctivitis

Interventions

  • Lastacaft ®Drug

  • Tears Naturale ® (Placebo)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Conjunctival Inflammation at 1 Hour (+30 Minutes) Post CAC on Day 1Time frame: 1 hour (+30 minutes) post CAC on Day 1
  2. Conjunctival Inflammation 1 Hour (+30 Minutes) Post CAC on Day 2Time frame: 1 hour (+30 minutes) post CAC on Day 2

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.